The FDA has boosted its collaboration channels with cancer drug manufacturers and healthcare providers to improve the US supply of cisplatin, carboplatin and methotrexate, according to a White House press release from Tuesday.
The cisplatin shortage first appeared in February, and carboplatin appeared in May. Methotrexate injections entered the shortage list in March, and its tablet form entered in July.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.